Start with what life feels like now
What does research say about TPE and EBOO?
We help people with questions about whether another treatment is worthwhile by explaining evidence alongside individual findings so that they can weigh the options with realistic expectations.
How we look at the whole picture
A treatment may sound promising, but you want to know what has actually been studied and what remains uncertain.
You need room to ask about risks, alternatives and the possibility that an option will not help.
You do not need to know which treatment to ask for. Start with what has changed and what you want to be able to do again.
The 7 Domains of Recovery™
Your symptoms may belong in the same conversation.
The seven domains organize the assessment; they do not establish that a particular treatment will work. Each proposed option still needs its own evidence and suitability review.
Neuregen's proprietary 7 Domains of Recovery framework organizes that conversation around seven connected parts of your life and health. We consider all seven, then focus the evaluation on the questions your history raises.
Explore our clinical framework- 1Brain function & neural networks
What has changed in your memory, concentration, balance or sensory tolerance?
- 2Autonomic & nervous system regulation
What happens when you stand, move, rest or encounter stress?
- 3Immune function & neuroinflammation
What immune history, reactions or symptoms need a closer look?
- 4Brain energy & metabolic health
What affects your energy through the day and after activity?
- 5Structure, stability & body-to-brain signals
How do pain, posture, movement and stability affect what you can do?
- 6Psychological flexibility & behavioral recovery
How are mood, stress and patterns of coping affecting your day?
- 7Life, relationships & environment
What demands, relationships and support shape your recovery?
A plan starts with the things you want to do again.
We begin with the problem you want help with. After reviewing the findings, we discuss the evidence, risks, alternatives and what would make us reconsider a recommendation.
01
Tell us what you want your life to look like
We start with what has changed, what you have tried, and the activities you most want to return to.
02
Answer the questions the history leaves open
We review prior reports and select relevant assessments. You should understand what each assessment is meant to clarify.
03
Agree on the priorities and the first steps
We discuss the findings, possible approaches, costs and practical constraints. The plan sets an order that fits your situation.
04
Check what changes and adjust together
We compare your response with the starting point, including daily function. If something is not helping, we discuss what needs to change.
Only then do we discuss which therapies, if any, belong in your plan. The choice depends on the findings, the evidence, your preferences and how you respond.
Talk through your situationBlood Rehabilitation
Research & Evidence: Blood Rehabilitation at Neuregen
Established medicine where it works. Emerging medicine where it makes sense. Rehabilitation throughout.
Conceptual artwork for the care discussion. Individual findings and treatment options require clinical evaluation.
Evidence for each specific use
Neuregen's evidence-labeling system exists for a specific reason: promising does not mean proven. Promising deserves serious investigation. The same therapy can be established for one indication and investigational for another — and those distinctions matter for informed consent and realistic expectations.
Therapeutic Plasma Exchange has an established evidence base for classic autoimmune neurologic disease: Guillain–Barré syndrome, Myasthenia gravis, certain forms of autoimmune encephalitis. For Alzheimer's disease, Neuregen draws on the AMBAR line of investigation — a multi-center trial of plasma exchange with albumin replacement in mild-to-moderate Alzheimer's — with moderate evidence for the studied protocol and important uncertainty. For mold-related neurologic illness, Long COVID neuroinflammation, and MCAS with CNS-dominant symptoms, the evidence is early-stage and the designation is investigational.
EBOO / EBO2 is designated investigational for neuroinflammatory and metabolic support. Proposed mechanisms include support for oxygen utilization, redox signaling, and cellular energy, as well as immunomodulatory effects. Evidence for these mechanisms in the specific applications Neuregen targets is evolving.
The AMBAR trial was a multicenter, industry-funded randomized study. Neuregen is not affiliated with AMBAR, does not run it, and does not replicate it. Neuregen applies AMBAR-informed principles within its own clinical and rehabilitation framework.
Domains most involved:
Every plan starts from the same map: the 7 Domains of Recovery.
How it fits your plan
Understanding the evidence is part of making an informed decision. This page explains which uses are established, emerging or investigational so you can bring specific questions to the consultation.
Blood therapies only make sense in relation to a specific clinical question. We review the indication, evidence and risks for TPE or EBOO separately, then consider whether either has a role alongside rehabilitation and your existing medical care.
We review your history, explain the findings, agree on next steps and check how you respond.
Evidence by tier
We use established medicine where it works, and emerging medicine where it makes sense.
These are options to discuss after evaluation, not a predetermined treatment plan. Each label refers to the condition or indication described beside that therapy; evidence can differ for another use. An evidence label does not mean FDA approval.
- ESTABLISHED — TPE for classic autoimmune neurologic diseaseEvidence: Established
Supported by established clinical guidelines for indications such as Guillain–Barré syndrome, Myasthenia gravis, and certain forms of autoimmune encephalitis.
- MODERATE — Albumin-based TPE for mild-to-moderate Alzheimer's diseaseEvidence: Moderate
Plasma exchange with albumin replacement has moderate evidence for slowing decline in mild-to-moderate Alzheimer’s disease. AMBAR found less decline in daily function; its overall cognitive result favored treatment but did not meet the conventional statistical-significance threshold. This remains a developing approach, not an established standard of care.
- INVESTIGATIONAL — TPE for mold, Long COVID, and MCASEvidence: Investigational
Early-stage evidence; offered with explicit informed consent and no outcome guarantee for mold-related neurologic illness, post-viral neuroinflammatory presentations, and MCAS with CNS-dominant symptoms.
- INVESTIGATIONAL — EBOO / EBO2 for metabolic and brain-energy supportEvidence: Investigational
Early-stage evidence; proposed mechanisms include support for oxygen utilization, redox signaling, and cellular energy. Offered as an investigational adjunct within a broader rehabilitation plan.
Where the evidence stands
The strength of evidence varies by the specific use. TPE is established for classic autoimmune neurologic disease; moderate evidence for the studied albumin-replacement protocol in Alzheimer's; investigational for mold-related illness, Long COVID, and MCAS. EBOO is investigational for neuroinflammatory and metabolic support. Neuregen labels each use at the consultation — the most honest conversation is the first one.
- AMBAR trial: Plasma Exchange and Albumin Replacement in Alzheimer's Disease (multi-center randomized research study)
- ASFA guidelines: Therapeutic Plasma Exchange indications and evidence classifications
Sources and what they support
- ASFA 2023 guidelines for therapeutic apheresis
Apheresis recommendations are indication-specific. An established use for one disease does not establish TPE for Alzheimer’s, Long COVID, MCAS or environmental illness.
How we grade evidence
The training behind this care
Neuregen brings the blood-therapy discussion into the same plan as neurologic, autonomic and functional care. We ask what a proposed intervention would change in daily life and how that change would be assessed.
Dr. David George: Board certifications and training in functional neurology, integrative psychiatry, and mental health; certified brain injury specialist.
Training most relevant to this area
- Member, American Society for Apheresis (ASFA)
- GCP Certified (NIDA)
These are the founder’s qualifications. We confirm the treating clinician and their role when discussing your plan.
See Dr. George’s full credentialsFrequently asked questions
Is Neuregen affiliated with the AMBAR trial?
No. AMBAR was an multi-center randomized research trial. Neuregen draws on the published findings and principles of that research to inform clinical practice for selected patients. Neuregen does not run the trial, is not affiliated with it, and does not replicate it.
How does Neuregen decide what evidence level to assign?
Neuregen’s five-level scale distinguishes Strong, Moderate, Emerging, Preliminary, and Investigational evidence. Existing Established labels describe established clinical uses and are not automatically assigned a numerical grade. Each designation is specific to the indication, not the therapy globally.
Is EBOO evidence-based?
EBOO has proposed mechanisms grounded in ozone chemistry and extracorporeal physiology, and is being studied in a range of conditions. For the specific applications Neuregen targets — neuroinflammatory and metabolic support — the evidence base is early-stage and evolving. Neuregen designates it investigational and says so clearly at every consultation.
Does Neuregen offer experimental treatments?
Neuregen offers investigational treatments — a defined category that means early-stage evidence or strong mechanistic rationale, offered with explicit informed consent and no outcome guarantee. This is distinct from experimental research: patients are not enrolled in a study. They receive clinician-directed care with full transparency about the evidence level for their specific indication.
Start with a Strategy Consultation
Ongoing fatigue or difficulty thinking may already be limiting your work and family life. An evaluation can help organize what is known, what remains uncertain and whether further investigation is useful before considering blood therapy.
8090 N. 85th Way, Suite 100, Scottsdale, AZ 85258 · Mon–Thu, 9:00 AM – 5:30 PM